(571b) Immune Modulatory Biomaterials for Cell-Based Therapeutics
AIChE Annual Meeting
2020
2020 Virtual AIChE Annual Meeting
Materials Engineering and Sciences Division
Biomaterials in Industry and the Clinic (Invited Talks)
Friday, November 20, 2020 - 8:15am to 8:30am
Immune cell recognition of implanted biomedical devices initiate a cascade of inflammatory events that result in collagenous encapsulation of implanted materials which leads to device failure. These adverse outcomes emphasize the critical need for biomaterials that do not elicit foreign body responses. One prime example for the use of this technology towards the development of immunoisolation strategies to engineer implantable cell-based biologic delivering factories. These systems termed âliving therapeuticsâ is comprised of polymer encapsulated engineered cells that produce and secrete of biologic (cytokine, hormones, and antibodies) of interest with sense and respond capabilities to match physiological needs for therapies. We have developed this technology towards to treatment of a number of diseases. Here, I will highlight our advances towards the treatments of: 1) Type1 diabetes by delivering glucose responsive insulin producing cells, and 2) peritoneal cancers by delivering therapeutic cytokines to stimulate cancer immunotherapy.